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Abstract
Background: In the context of the WHO’s 2016 Viral Hepatitis Strategy and the introduction of treatment that
can cure more than 95% of cases with hepatitis C virus (HCV) infection, the European Joint Action on HIV
and Co-infection Prevention and Harm Reduction (HA-REACT) undertook a study in the member states of the
European Union (EU). It aimed to determine service providers’ understanding of the current services in their
respective countries and the barriers experienced by PWID in accessing HCV testing, care and treatment
services in their country.
Methods: In 2017, 38 purposively selected harm reduction service providers completed a 26-item English-
language online survey addressing the availability, accessibility and funding of HCV services at harm reduction
centres. HCV-related data and reported findings were extracted by country or by responding organization.
Results: Responses were received from all EU member states. Respondents from 23 countries reported that
HCV tests are offered by harm reduction services in their countries, and eight countries reported that
addiction specialists in their countries are able to prescribe HCV therapy. Almost half of the respondents
(45%) said that their respective organizations had established referral systems with centres providing HCV
treatment.
Conclusions: Not all EU member states have harm reduction services that provide HCV tests, and many do
not have established referral systems with treatment providers. Moreover, the inability of addiction specialists
to prescribe HCV treatment points to missed opportunities to make treatment more accessible. Further,
discrepancies were noted between the available HCV services and stakeholders’ knowledge about their
availability.
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Key points
There are important gaps in the HCV cascade of care in
harm reduction services in several EU member states
and discrepancies between the availability of these ser-
vices and stakeholders’ knowledge. These include testing
provision, referral systems and prescription of HCV
treatment by addiction specialists.
Introduction
An estimated 15.6 million people injected illicit drugs
worldwide in 2017 [1]. In the absence of appropriate
harm reduction measures, people who inject drugs
(PWID) are disproportionately impacted by infectious
diseases, viral infections among them. Today, injecting
drug use remains the world’s single largest risk factor for
the transmission of hepatitis C virus (HCV) [2], an epi-
demic that has chronically infected an estimated 71 mil-
lion people as of 2015, accounting for approximately 1%
of the world’s population [3, 4]. Left untreated, infection
with HCV can lead to cirrhosis, liver failure and
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hepatocellular carcinoma [4]. The rate of progression
and time to liver fibrosis and related complications are
similar among PWID and HIV-uninfected people living
with HCV [5].
The growing recognition of the global burden of hepa-
titis has led to the emergence of a recent, internationally
coordinated response. Major international organizations,
including the European Monitoring Centre for Drugs and
Drug Addiction (EMCDDA) [6], European Centre for Dis-
ease Prevention and Control (ECDC) [7] and World
Health Organization (WHO) [8], recommend that preven-
tion, vaccination, diagnosis and treatment of viral hepatitis
be available to PWID as part of a comprehensive harm re-
duction package. In 2016, WHO published its landmark
Global Health Sector Strategy on Viral Hepatitis, 2016–
2021 (GHSS) with the explicit goal of eliminating viral
hepatitis “as a public health threat” by 2030 [9]. The core
of GHSS relies on the so-called HCV cascade of care,
which comprehensively summarizes the status of the
HCV continuum of care in a particular setting, thereby
acting as the key organizing framework for monitoring. It
provides an overview of the status of the total number of
estimated HCV cases: the number tested, diagnosed and
confirmed, referred to specialist care, treated and cured
[9]. On-site testing services at harm reduction centres,
pre-test counselling and education, dried blood spot test-
ing, facilitated referral for HCV assessment and scheduling
of specialist appointments have proved useful in enhan-
cing access to various stages of the cascade, including for
vulnerable populations such as the homeless, the unin-
sured, PWID and other populations that may otherwise
have no access to formal medical facilities [10, 11].
Injecting drug use is the main source of HCV infection
in the European Union (EU), accounting for more than
80% of new infections [12]. PWID bear a significant bur-
den of viral disease [13, 14], and the guidelines of the
European Association for the Study of the Liver (EASL)
recommend that they be evaluated for treatment [15].
Therefore, the governments are tasked by the WHO
GHSS [9] with making comprehensive efforts to provide
HCV-specific harm reduction services to PWID, which
should be tailored to the continuum-of-care services for
HCV [16–18]. Modelling studies conclude that a massive
scale-up of testing and treatment is needed to reach the
WHO elimination goals by 2030 [19]. However, fewer
than half of the EU countries have national HCV strategies
or action plans, and even fewer specifically address the
needs of PWID in their hepatitis response documents.
Moreover, the prevention, testing, linkage to care and
treatment needs of HCV patients are far from being uni-
versally addressed in the EU [20, 21].
HCV is systematically underdiagnosed in Europe [22,
23], especially among PWID [24]. In addition, specific
barriers hinder the inclusion of PWID and their linkage
to the HCV cascade of care, and most PWID are largely
unaware of their disease status [22–24] and of the avail-
ability of curative treatment regimens [25]. Some mem-
bers of marginalized groups are so stigmatized that they
hesitate to seek help [26, 27], and not all health systems
are equipped to manage the complex social situations or
health profiles of PWID. PWID are also deterred from
seeking help from the authorities due to the
criminalization of drug use, discrimination in healthcare
settings and other violations of human rights [28]. As a
result, few people living with HCV in Europe have re-
ceived treatment and, until recently, drug use has been a
common criterion for treatment ineligibility [29, 30].
The availability of services for the HCV cascade of care
and national strategies for eliminating HCV has been
identified as a key issue for the success of the WHO
GHSS [31]. The aim of this study was to determine
HCV service provision in harm reduction centres in all
EU member states.
Methods
Harm reduction services were defined as those activities
and resources that encompassed opioid substitution
therapy (OST), needle and syringe programmes (NSP)
and the generic cross-cutting aspects of harm reduction
[32]. These harm reduction services were referred to as
being ‘free of charge’ if the client obtained them for free.
HCV care was defined as activities that involved testing,
linkage to care, counselling, treatment and surveillance
of complications.
An online survey was developed and conducted by part-
ners in the EU Joint Action on HIV and Co-infection Pre-
vention and Harm Reduction (HA-REACT), with
substantial input from the Correlation Network [33]. The
survey was sent out on 29 March 2017 to relevant mem-
bers of the Correlation Network providing or organizing
harm reduction services in the 28 EU member states. Due
to the unique health system structure of the UK and
Spain, both of which are highly decentralized with subna-
tional bodies managing the service, for the UK, surveys
were sent to organizations in England and Scotland, and
for Spain, they were sent to the Basque Country and Cata-
lonia. Follow-up emails and calls were sent to participating
organizations until responses from at least one
organization in each of the EU member states were re-
corded. The survey was closed on 17 May 2017.
Simple frequency analysis was conducted of the replies
to each survey question in each of the EU member states,
for entities both organizing and providing harm reduction
services. In cases where multiple responses were received
from a country and the answers were concordant, this an-
swer was reported as the overall response from the re-
spective country. In cases where the responses were
discordant between organizers and providers of harm
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reduction services, the response from the harm reduction
service provider was accepted as the overall response from
the country, since service providers were the main respon-
dents. Where both parties were harm reduction service
providers and the responses were discordant, the response
was marked as inconclusive. These criteria were not ap-
plied to the UK or Spain, as the health systems of those
countries necessitated that responses from different parts
of the country be reported separately.
Results
Thirty-eight harm reduction service providers from the 28
EU member states responded to the survey. Since England
and Scotland reported separately as they have different
healthcare systems, as is the case with the Basque Country
and Catalonia in Spain, the total number of responses was
30. There were two responding harm reduction service
entities from Belgium, Bulgaria, the Czech Republic,
France, Lithuania, Poland and the UK. Three respondents
were from Italy and Spain. The rest of the EU member
states had only one respondent each.
Testing
Twenty-three out of the 30 respondents (77%) reported
that at least some harm reduction service providers offer
HCV testing in their respective countries or regions. Five
(17%; Croatia, Cyprus, Lithuania, Poland and Slovakia) re-
ported that HCV testing is not available at any harm reduc-
tion service in their respective country or region, and two
(7%; Basque Country and Slovenia) did not know (Table 1).
Follow-up comments
 Cyprus: harm reduction service providers must refer
patients to hospitals for treatment. However,
training in rapid testing was expected to start in
2017, and staff working in harm reduction and
treatment services will be able to provide HCV
testing to Cypriot patients at some point between
2017 and 2020.
 Germany: even though harm reduction service
providers can technically provide HCV testing, in
practice, very few providers offer this service.
Twenty-six out of 29 respondents (90%; responses
from Belgium were discordant and therefore removed
from further analysis) reported that HCV testing is gen-
erally available free of charge in their respective coun-
tries or regions. Respondents from three countries (10%;
Greece, Lithuania, Sweden) reported that HCV testing is
generally not available free of charge in those countries.
Care
Respondents from 26 of 30 (87%) countries or
semi-autonomous regions reported that harm reduction
service providers are involved in at least one aspect of
managing HCV care. Two of the 30 (7%; Slovakia and
Sweden) reported that harm reduction service providers
are not involved in any aspect of managing HCV care,
and two respondents (7%; Basque Country and Slovenia)
did not know (Table 2).
Follow-up comments
 Belgium: clarified that there is a pilot “HCV Buddy
Project” that helps guide patients through treatment
and care.
 Czech Republic: added that harm reduction service
providers offer case management to HCV patients.
Twenty-nine out of 30 respondents (97%) reported
that NSP are generally available free of charge in their
respective countries or regions. Only the respondent
from Bulgaria reported that NSP were not available free
of charge in that country (Table 3).
Twenty-seven out of 29 respondents (93%; the responses
from Belgium were discordant and therefore removed from
analysis) reported that OST was available free of charge in
their respective countries or regions. Respondents from
three countries (10.3%; Bulgaria, Czech Republic and
Sweden) reported that OST was not available free of charge
in that country. The reply from Sweden showed a disagree-
ment between the knowledge of national policies among
stakeholders and the policies actually in place.
Respondents from 27 out of 30 (90%) countries reported
that counselling was generally available free of charge in
their respective countries or regions. Respondents from
three countries (10%; Bulgaria, Denmark, Greece) re-
ported that counselling was not available free of charge in
those countries. The reply from Denmark showed a dis-
agreement between the knowledge of health services
among stakeholders and the services actually in place.
Follow-up comments
 Cyprus: clarified that care is generally free of charge
at all government hospitals. For those clients who
are not hospital card holders and are not citizens of
Cyprus or the EU, there is a special system in place
where the Ministry of Health can authorize free
access to treatment. This is especially relevant for
migrants from outside the EU.
Treatment
Of the respondents in countries or semi-autonomous re-
gions that had HCV tests available at harm reduction
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services (n = 27), 17 (63%) reported that their respective
organizations had established referral systems with hos-
pitals or clinics that provide HCV treatment (Table 4).
Eight out of 30 respondents (27%; Cyprus, the Czech
Republic, Denmark, England, Germany, Luxembourg,
Romania and Slovenia) reported that addiction special-
ists could prescribe HCV treatment in those countries
or regions. Respondents from 20 of 30 (67%) countries
or semi-autonomous regions reported that addiction
specialists could not prescribe HCV treatment, and re-
spondents from two countries (Ireland and Latvia) did
not know (Table 5).
Discussion
This study shows that at harm reduction services, the
HCV cascade of care for PWID is severely constrained
by a number of barriers in EU member states. This wor-
risome situation puts at risk the achievement of the
Table 1 EU member states in which hepatitis C tests are offered by any harm reduction service in the country and type of harm
reduction services they offer (N = 30)
Hepatitis C tests are offered by any
harm-reduction service in the country





Mental health services required to obtain




Belgium Yes * * *
Bulgaria Yes x Not specified
Croatia No
Cyprus No







Hungary Yes x x











Slovenia Do not know
Spain (Barcelona) Yes






Do not know = 2
n = 4/28 n = 3/28 n = 3/28 n = 1 n = 0
x: the respondent states that harm reduction services provide the HCV service in his/her country
*Answers from respondents differed, indicating that barriers may be dependent on the organization and differ within the country
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WHO HCV elimination goals in the EU and entails a
high burden of disease and financial consequences for
the EU population as a whole (e.g. not only direct med-
ical costs, often with highly expensive procedures such
as liver transplantation, but also indirect costs as those
due to decreased work productivity) [34–38]. Health au-
thorities at the EU and country levels should therefore
take measures to overcome the challenges of eliminating
HCV among PWID in a way that preserves human
rights and mitigates health inequalities [39].
Testing
HCV tests are offered by harm reduction service providers
in the majority of EU member states, except in about one
fifth of the countries and semi-autonomous regions sur-
veyed. Respondents also indicated that HCV testing was
not free of charge in three EU member states.
The Hep-CORE study conducted by the European
Liver Patients’ Association was similar to ours but in-
cluded responses from seven non-EU countries [20]. It
showed that free HCV testing was available in one third
of the countries in 2016. As EU member states are gen-
erally wealthier and have larger budgets for healthcare
services than their European non-EU counterparts,
non-EU countries could be less likely to have free HCV
testing available than EU countries. According to the
Hep-CORE study, patient groups also reported that
about half of their respective countries had testing avail-
able outside of hospitals for the general population. This
figure was also significantly higher in our survey.
According to a 2016 data from the EMCDDA, only
47.4% of the countries assessed had over 50% OST
coverage for high-risk opioid users and just 26.7% had
high coverage of specialized NSP [40]. This shortage of
harm reduction services is a major barrier to connecting
PWID to testing [41, 42], as facilities providing harm re-
duction services are usually in a better position than
healthcare settings to contact and test members of the
community. Moreover, the fact that not all EU countries
have testing available at harm reduction services indi-
cates a missed opportunity. Policies regarding HCV test-
ing should be amended to solve this problem, including
the implementation of point-of-care testing to improve
the coverage of diagnosis, among others [43]. It has fur-
ther been shown that PWID are more likely to be tested
for HCV if they have access to point-of-care HCV anti-
body testing rather than testing at traditional healthcare
sites [44]. Moreover, there is evidence that screening is
cost effective and helps lessen the financial burden of
HCV on health systems [45].
Care
Respondents in our survey reported that harm reduction
service providers in two countries or regions were not
involved in managing any aspect of HCV care. Perhaps
the most striking finding was that respondents from two
thirds of the EU member states or regions reported that
addiction specialists could not prescribe HCV treatment,
in spite of PWID being one of the highest burden
HCV-infected populations in Europe. These results sug-
gest that targeted efforts are needed to expand on-site
testing services at harm reduction facilities in Croatia,
Cyprus, Lithuania, Poland and Slovakia, and potentially
in Slovenia and Spain’s Basque Country as well. Al-
though pre-test counselling and dried blood spot testing
Table 2 EU member states in which organizations that provide
services to PWID are involved in managing any aspect of


























Slovenia Do not know
Spain (Barcelona) Yes




Total Yes = 26
No = 2
Do not know = 2
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were not a focus of our survey, these services should be
included in all existing and future testing services of
harm reduction service providers in the EU.
Treatment
Despite the existence of an effective biomedical cure, the
socioeconomic and health system realities of the disease
currently hamper the possibility of global HCV elimin-
ation. Reimbursement restrictions and the high prices of
direct-acting antivirals (DAAs) limit their accessibility,
even in high-income countries [46, 47]. DAAs are
effective in achieving a sustained virological response in
patients, effectively curing them [15]. PWID attending
harm reduction services can achieve the same level of
adherence as the general population [48, 49], including
when treatment is provided at the community level [50].
Our study shows that addiction specialists are able to
prescribe DAAs only in a handful of EU member states.
The issue of whether addiction medicine specialists
should be allowed to prescribe DAAs to widen the scope
of treatment, or whether linkage to care from harm re-
duction centres to infectious disease specialists and
Table 3 Harm reduction and health services generally free of charge for PWID (N = 30)
NSP OST Counselling HIV testing HCV testing ART HCV treatment
Austria x x x x x x x
Belgium x * x x * * *
Bulgaria x x x
Croatia x x x x x x x
Cyprus x x x x x x x
Czech Republic x x x x x x
Denmark* x x x x x x
Estonia x x x x x x x
Finland x x x x x x x
France x x x x x x x
Germany x x x x x x x
Greece x x x x
Hungary x x x x x x x
Italy x x x x x x x
Ireland x x x x x x x
Latvia x x x x x x x
Lithuania x x x x x
Luxembourg x x x x x
Netherlands x x x x x x x
Malta x x x x x x
Poland x x x x x x x
Portugal x x x x x x x
Romania x x x x x x
Slovakia x x x x x
Slovenia x x x x x x x
Spain (Barcelona) x x x x x x x
Spain (Bilbao) x x x x x x x
Sweden+ x x x x x
UK (London) x x x x x x x
UK (Glasgow) x x x x x x x
n = 29 n = 26/29 n = 27 n = 29 n = 26/29 n = 27/29 n = 23/29
x: the respondent states that harm reduction services provide the HCV service in his/her country
*According to information shared by EMCDDA, Denmark has psychosocial counselling as part of treatment
programmes (http://www.emcdda.europa.eu/countries/drug-reports/2017/denmark/treatment_en)
+According to information shared by EMCDDA, Sweden provides OST free of
charge (http://www.emcdda.europa.eu/countries/drug-reports/2017/sweden/treatment_en)
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hepatologists should be improved has generated a con-
troversy. Pivotal studies performed in Australia have
provided valuable insight pointing to the feasibility, cost
efficacy and lower rates of follow-up losses when prop-
erly educated, and trained addiction doctors are directly
involved in HCV treatment [51, 52]. From our perspec-
tive, this approach needs to guarantee that the HCV cas-
cade of care is available to PWID so as to achieve the
WHO elimination goals.
Previous studies have shown that financial barriers
prevented HCV patients in Eastern EU member states
from accessing HCV treatment in the era of
interferon-based therapies [53]. In Romania, for ex-
ample, the high costs of treatment resulted in 89% of pa-
tients diagnosed with chronic HCV forgoing treatment
[54]. In Romania, the reimbursement scheme does not
seem to have changed, as the respondent from Romania
in the present survey said that HCV treatment is not
provided to patients free of charge.
Limitations
The greatest limitation of our study is that it surveyed
only harm reduction service providers, who are not
Table 4 EU member states in which there is an established
referral system with a hospital or clinic that provides hepatitis C







Czech Republic (Prague) Yes
























*Respondents who reported that HCV testing is available in their countries
Table 5 EU member states in which addiction specialists can
















Ireland Do not know

















Do not know = 2
Pericàs et al. Harm Reduction Journal           (2019) 16:20 Page 7 of 10
necessarily able to report on national health policy and
governance. Therefore, there may be discrepancies be-
tween harm reduction providers’ perception or under-
standing of policy, and the policy as it is written—such
as the cases highlighted from Sweden and Denmark.
Further, as many of the questions in the survey were not
open-ended, the complexities of policy as it plays out in
practice may have been lost. Even if DAA treatment is
available, there are restrictions in prescribing them [20].
Our study did not review any such restrictions, and
therefore some of the countries where we report that
DAAs are available may not provide these to all HCV
patients.
In addition, our survey does not report the availability
of dried blood spot testing, although this has been
shown to be a simpler diagnostic tool [10].
Conclusions
Eliminating hepatitis C as a public health threat requires
a concerted effort targeting PWID. This study shows
that, according to providers, not all EU member states
have harm reduction services that are suited for this pur-
pose. The services available were reported to lack both
HCV testing and an established referral system to HCV
treatment providers. Furthermore, in many countries,
addiction specialists are not authorized to prescribe
HCV treatment. Finally, discrepancies were noted be-
tween national policies in place and harm reduction
stakeholders’ knowledge of and information about these
policies, indicating a gap between policy and practice.
The way forward requires a multifaceted response in-
volving at least the following aspects. First, HCV tests
should be available at all harm reduction facilities. Sec-
ond, current prescribing restrictions should be over-
come, and addiction doctors should be able to provide
HCV treatment to optimize its accessibility. Third, HCV
medication should be made free of charge for patients.
And fourth, practice and policy should be reviewed at
the national and sub-national levels, and stakeholders
should be involved to a greater degree in the develop-
ment of policies to ensure better implementation. Im-
proving prevention, treatment and care for PWID is in
line with the United Nations comprehensive package’s
recommendation that PWID be diagnosed and treated
for viral hepatitis.
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